Your browser is no longer supported. Please, upgrade your browser.
Settings
CELG Celgene Corporation daily Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E16.94 EPS (ttm)5.53 Insider Own0.10% Shs Outstand699.17M Perf Week-0.50%
Market Cap65.55B Forward P/E7.41 EPS next Y12.66 Insider Trans-3.25% Shs Float699.17M Perf Month6.10%
Income4.05B PEG0.94 EPS next Q2.44 Inst Own78.00% Short Float2.65% Perf Quarter8.28%
Sales15.28B P/S4.29 EPS this Y5.90% Inst Trans1.04% Short Ratio1.81 Perf Half Y11.25%
Book/sh8.81 P/B10.64 EPS next Y18.14% ROA11.80% Target Price96.78 Perf Year3.02%
Cash/sh8.64 P/C10.85 EPS next 5Y17.96% ROE82.50% 52W Range58.59 - 95.44 Perf YTD46.29%
Dividend- P/FCF13.54 EPS past 5Y26.80% ROI16.70% 52W High-1.76% Beta1.72
Dividend %- Quick Ratio2.10 Sales past 5Y18.70% Gross Margin96.20% 52W Low60.03% ATR1.36
Employees8852 Current Ratio2.20 Sales Q/Q15.90% Oper. Margin34.00% RSI (14)55.44 Volatility1.15% 1.42%
OptionableYes Debt/Eq3.29 EPS Q/Q-2.20% Profit Margin26.50% Rel Volume1.00 Prev Close94.30
ShortableYes LT Debt/Eq3.21 EarningsMay 02 BMO Payout0.00% Avg Volume10.21M Price93.76
Recom2.80 SMA201.29% SMA504.34% SMA20011.76% Volume10,240,094 Change-0.57%
Apr-01-19Downgrade William Blair Outperform → Mkt Perform
Apr-01-19Downgrade UBS Buy → Neutral $94 → $102
Apr-01-19Downgrade Atlantic Equities Overweight → Neutral
Feb-01-19Downgrade Jefferies Buy → Hold $95
Jan-04-19Upgrade Robert W. Baird Neutral → Outperform
Jan-04-19Upgrade Goldman Sell → Neutral
Dec-21-18Resumed BTIG Research Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Apr-19-19 12:19PM  5 Top Biotech Stocks to Buy in 2019 Motley Fool
11:02AM  5 Top Healthcare Stocks to Buy in 2019 Motley Fool
Apr-17-19 12:11PM  Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's exchange notes; under review for downgrade Moody's
08:18AM  Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes Business Wire
07:48AM  Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal Zacks
Apr-16-19 10:52AM  Why Amgen Stock Could Break Out to New Highs InvestorPlace
06:00AM  Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition Closes Motley Fool
Apr-15-19 05:54PM  David Rolfe Comments on Celgene GuruFocus.com
05:45PM  Celgene (CELG) Gains As Market Dips: What You Should Know Zacks
05:02PM  David Rolfe's Wedgewood Partners 1st-Quarter 2019 Client Letter GuruFocus.com
01:53PM  Bristol-Myers' Shareholders Vote for Celgene Acquisition Zacks
Apr-12-19 06:56PM  Bristol-Myers CEO: We're 'one step closer to creating that great company' with Celgene CNBC Videos
06:50PM  'One step closer to creating that great company' with Celgene, says Bristol-Myers CEO CNBC Videos
06:32PM  Bristol-Myers CEO: We're 'one step closer to creating that great company' with Celgene CNBC
01:21PM  Bristol-Myers says shareholders vote to approve Celgene takeover Reuters
11:11AM  Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up TheStreet.com
11:00AM  Bristol-Myers says shareholders vote to approve Celgene takeover Reuters
10:49AM  Bristol-Myers shareholders approve drugmaker's $74 billion deal with Celgene CNBC
10:33AM  Celgene Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb Business Wire
07:23AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
12:28AM  Bristol-Myers shareholders approve $90bn Celgene takeover Financial Times
Apr-11-19 09:46AM  Concert Pharma Initiates Early-Stage Schizophrenia Study Zacks
08:15AM  BMY Stock Looks Really Appetizing as the Celgene Merger Approaches InvestorPlace
06:01AM  Bull of the Day: Centene (CNC) Zacks
Apr-10-19 01:40PM  5 Oncology Companies That Are Set to Run GuruFocus.com
01:00PM  A Stupid Question About Stocks Yields a Surprising Answer Bloomberg
09:20AM  Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More Zacks
Apr-09-19 05:45PM  Celgene (CELG) Dips More Than Broader Markets: What You Should Know Zacks
Apr-08-19 06:11PM  Celgene & Acceleron Submit BLA for Luspatercept to the FDA Zacks
10:37AM  Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym Zacks
Apr-05-19 09:28AM  Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA Business Wire
08:00AM  Health Day Checkup of Medical ETFs: 5 Top Picks Zacks
Apr-04-19 03:54PM  Sorrento Therapeutics sues Soon-Shiong over alleged cancer drug scheme American City Business Journals
03:39PM  Editas (EDIT) Inks Cross Licensing Agreement with BlueRock Zacks
09:41AM  The Zacks Analyst Blog Highlights: Pfizer, Royal Dutch, Celgene, Advanced Micro and Blackstone Zacks
Apr-03-19 07:52PM  Activist Keith Meister Says This Years Market Rally and Last Decembers Sell-Off Made Us Break Even Insider Monkey
02:51PM  Top Research Reports for Pfizer, Royal Dutch Shell & Celgene Zacks
02:18PM  Is Celgene Stock Still Worth Holding Onto in the Long Run? InvestorPlace
04:41AM  Micron Technology, Tencent and two dozen other companies most likely to benefit from a China trade deal MarketWatch
01:50AM  Patrick Soon-Shiong accused of cancer drug catch and kill Financial Times
Apr-02-19 05:45PM  Celgene (CELG) Stock Moves -0.28%: What You Should Know Zacks
05:08PM  Why Celgene's Shares Soared 13.5% in March Motley Fool
03:06PM  You Can Play the Flurry of M&A With Merger Arbitrage Funds. Heres How They Work. Barrons.com
10:09AM  AVEO Reports Positive Results on Leukemia Drug, Shares Up Zacks
Apr-01-19 04:41PM  Celgene Remains In Buy Zone As Bristol Likely To Clinch Takeover Investor's Business Daily
04:24PM  Celgene Gets Positive CHMP Nod for Revlimid Label Expansion Zacks
02:12PM  Celgene Stocks Latest Leap Changes Wall Streets Math on Bristol-Myers Deal Barrons.com
10:49AM  Seattle Genetics Closes Enrollment in Cervical Cancer Study Zacks
10:34AM  Bristol-Myers' (BMY) Acquisition of Celgene Looks Certain Zacks
10:17AM  Company News For Apr 1, 2019 Zacks
10:15AM  Bristol-Myers Squibb/Celgene deal opponent backs off its opposition American City Business Journals
09:56AM  Celgene stock downgraded to neutral at UBS MarketWatch
09:25AM  The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage Zacks
08:53AM  3 Big Pharma Stocks to Add to Your Portfolio This April Zacks
08:43AM  Blueprint Medicines (BPMC) Looks Good: Stock Adds 5.7% in Session Zacks
Mar-31-19 11:02AM  Bristol-Myers Gets ISS Support for Celgene Takeover; Starboard Drops Opposition TheStreet.com
Mar-29-19 07:29PM  Lyft IPO and PCE Price Index Bring Out the Bulls Investopedia +7.88%
05:03PM  Stock Market Today: Lyft Goes Public Motley Fool
04:47PM  AVEO Pharmaceuticals (AVEO) to File NDA for Fotivda with FDA Zacks
04:31PM  Dow rallies more than 200 points as S&P 500 logs its best quarterly advance since 2009 MarketWatch
03:53PM  5 Top Stock Trades for Monday: Lyft, RH, Celgene, Wells Fargo InvestorPlace
01:57PM  Seattle Genetics, Astellas Report Positive Cancer Study Data Zacks
01:15PM  Stocks - S&P 500 Notches Best Quarter Since 2009 Investing.com
01:12PM  Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal Reuters
12:49PM  Proxy advisers ISS, Glass Lewis back Bristol-Myers takeover of Celgene Reuters
12:48PM  Starboard no longer urging investors to vote against Bristol-Celgene deal Reuters
12:48PM  Top Ranked Value Stocks to Buy for March 29th Zacks
12:40PM  Celgene's stock surges, after Starboard withdraws proxy fight of Bristol-Myers buyout deal MarketWatch
12:38PM  Starboard Ends Proxy Fight at Bristol-Myers Ahead of Vote Bloomberg
12:30PM  Celgene Stock Breaks Out As Bristol Grabs Key Merger Endorsement Investor's Business Daily
10:53AM  Celgene Stock Is Surging After ISS Backs Bristol Deal Barrons.com
09:35AM  Proxy advisor ISS backs Bristol takeover of Celgene Reuters
08:12AM  Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma Business Wire
07:00AM  Bristol-Myers/Celgene Deal Is About to Face a Crucial Test Barrons.com
Mar-28-19 10:18PM  Bristol-Myers wins backing of big advisers on $90bn Celgene deal Financial Times
04:34PM  Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks? Motley Fool
11:46AM  Top Ranked Value Stocks to Buy for March 28th Zacks
11:18AM  Blueprint Medicines Expediates Filings for Key Candidates Zacks
09:53AM  The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals Zacks
09:41AM  Jefferies' revenue hurt by U.S. govt. shutdown and weak markets in Dec. Reuters
Mar-27-19 11:14PM  Were Hedge Funds Right About Celgene Corporation (CELG)? Insider Monkey
02:47PM  5 Cancer-Fighting Stocks to Boost Portfolio Gains Zacks
10:48AM  Agios (AGIO) Surges More Than 40% Year to Date: Here's Why Zacks
10:45AM  Agios Gains Breakthrough Therapy Status for Tibsovo Combo Zacks
10:29AM  J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group Zacks
Mar-26-19 05:15PM  Celgene (CELG) Submits NDA for MS Drug to FDA for Review Zacks
04:19PM  Bristol-Celgene Deal Faces Hiccup As Officials Examine Psoriasis Drugs Investor's Business Daily
03:41PM  Celgene Stock Is Up Because Its FDA Application Is a Good Sign, Analyst Says Barrons.com
02:05PM  FTC focuses on psoriasis franchise for Bristol-Celgene deal review Reuters
11:59AM  FTC focuses on psoriasis franchise for Bristol-Celgene deal review Reuters
11:29AM  The Zacks Analyst Blog Highlights: RH, Foot Locker, Quanta, Celgene and CBRE Zacks
10:52AM  Top Ranked Value Stocks to Buy for March 26th Zacks
08:29AM  FTC seeks more information to review Bristol-Celgene's $74 bln planned merger Reuters
07:36AM  The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs Benzinga
07:32AM  Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal TheStreet.com
Mar-25-19 05:45PM  Celgene (CELG) Dips More Than Broader Markets: What You Should Know Zacks
04:30PM  Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis Business Wire
11:13AM  J&J Files Application for Darzalex Label Expansion in Europe Zacks
11:05AM  Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug Zacks
10:20AM  Top Ranked Value Stocks to Buy for March 25th Zacks
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; and EXSCIENTIA LTD. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alles Mark JCEO, CHAIRMAN OF BOARDMar 01Option Exercise0.0033,8090226,178Mar 05 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Option Exercise22.4724,666554,24562,102Feb 11 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Sale87.2923,4662,048,32438,636Feb 11 04:05 PM
MARIO ERNESTDirectorDec 19Option Exercise59.068,600507,87363,013Dec 20 04:48 PM
Biller JonathanEVP AND GENERAL COUNSELDec 16Option Exercise0.001,90004,046Dec 18 06:45 PM
VESSEY RUPERTSEE REMARKSDec 16Option Exercise0.005,35009,887Dec 18 06:43 PM
Curran TerrieSEE REMARKSDec 16Option Exercise0.002,50009,151Dec 18 06:28 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYDec 16Option Exercise0.003,000013,038Dec 18 06:26 PM
Alles Mark JCEO, CHAIRMAN OF BOARDDec 16Option Exercise0.008,9290196,245Dec 18 06:25 PM
MARIO ERNESTDirectorNov 26Option Exercise59.0610,000590,55054,413Nov 28 04:05 PM
MARIO ERNESTDirectorAug 09Sale92.3212,0001,107,88844,413Aug 13 04:05 PM
BARKER RICHARD WDirectorJun 17Option Exercise0.001,000012,846Jun 18 04:00 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00334037,436Jun 18 04:00 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00334056,413Jun 18 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037501,250Jun 15 04:57 PM
Friedman Michael ADirectorJun 15Option Exercise0.002,41300Jun 15 04:12 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441037,102Jun 15 04:13 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 15 04:16 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037501,050Jun 15 04:17 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375056,079Jun 15 04:23 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300055,704Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.003000675Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300034,661Jun 15 04:13 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 15 04:12 PM
Haller Julia ADirectorJun 14Option Exercise0.003000875Jun 15 04:57 PM
COX CARRIE SMITHDirectorJun 12Option Exercise0.006,200030,080Jun 14 04:35 PM
CASEY MICHAEL DDirectorJun 07Option Exercise30.0127,750832,77827,750Jun 11 04:06 PM
CASEY MICHAEL DDirectorJun 07Sale78.7713,0001,024,0100Jun 11 04:06 PM
LOUGHLIN JAMES JDirectorJun 04Option Exercise30.0127,750832,77852,111Jun 05 04:15 PM
LOUGHLIN JAMES JDirectorJun 04Sale78.9617,7501,401,54034,361Jun 05 04:15 PM
Masoudi GeraldSEE REMARKSJun 01Option Exercise0.0015,000020,235Jun 05 04:09 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 09Buy82.601,20899,784187,316May 17 04:08 PM
Curran TerrieMay 04Option Exercise0.002,50007,507May 08 04:56 PM
VESSEY RUPERTMay 04Option Exercise0.0078103,731May 08 04:36 PM
KELLOGG PETER NMay 04Option Exercise0.003,500050,831May 08 04:34 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 04Option Exercise0.003,5000187,627May 08 04:30 PM